Background. The epidemiology of streptococcal infection in pregnant and postpartum women is poorly described in recent literature. We used data from multistate surveillance for invasive Streptococcus pneumoniae, group A Streptococcus (GAS), and group B Streptococcus (GBS) infections to estimate disease incidence and severity in these populations.
immunologic response; several diseases thought to be caused by an autoimmune response, including hepatitis, thyroiditis, and cardiomyopathy, are associated with the postpartum state [4] [5] [6] [7] .
Studies of influenza and pregnancy suggest that pregnant women have an increased disease incidence and severity of illness, compared with nonpregnant women, both for seasonal influenza [8] [9] [10] and the 2009 H1N1 strain [11] . These findings led the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention (CDC) to recommend influenza vaccination for all women who will be pregnant during influenza season [12] .
Streptococcus pneumoniae (pneumococcus), group A Streptococcus (GAS), and group B Streptococcus (GBS) are leading causes of community-acquired invasive bacterial infections in the United States [13] [14] [15] . The pneumococcal polysaccharide vaccine is recommended for certain adult populations at risk for severe, invasive disease, but there are no recommendations regarding vaccination during pregnancy or after delivery. GAS and GBS vaccines are under development [16, 17] .
Although there are many case reports about invasive streptococcal disease in pregnant and postpartum women, the overall incidence and characteristics of these invasive infections in pregnant and postpartum women have not been systematically compared with those in nonpregnant women. Pneumococcal genital tract infections [18] , endometritis, peritonitis, and tuboovarian abscess in postpartum women have been described [19] [20] [21] . Several case reports detail postpartum GAS peritonitis, endometritis, and necrotizing infections [22] [23] [24] . GBS is known to cause urinary tract infection, intra-amniotic infection, and invasive disease during pregnancy, as well as postpartum endometritis [15, 25] .
We used population-based multistate surveillance for pneumococcus, GAS, and GBS to describe the burden and characteristics of infection in pregnant and postpartum women and to determine whether pregnant and postpartum women are at higher risk of these infections and of complications from these infections, compared with nonpregnant women.
METHODS

Study Population
Invasive infection due to pneumococcus, GAS, or GBS was defined as isolation of one of these pathogens from a normally sterile body site in a surveillance area resident during [2007] [2008] [2009] ; amniotic or placental fluid were not considered to be sterile. For GAS, invasive infection also included GAS isolation from a wound culture accompanied by necrotizing fasciitis or streptococcal toxic shock syndrome. Case patients were identified by the Active Bacterial Core Surveillance (ABCs), an active laboratory-and population-based surveillance system [26] in the following areas: California (San Francisco County), Colorado (5 county Denver area), Connecticut, Georgia (20 county Atlanta area), Maryland (6 county Baltimore area), Minnesota, New Mexico, New York (15 county Rochester and Albany areas), Oregon (3 county Portland area), and Tennessee (11 urban counties).
Clinical microbiology laboratories in acute care hospitals and reference laboratories processing sterile site specimens from surveillance area residents are contacted regularly for case identification. For each case, demographic and epidemiologic information are abstracted from medical records. The surveillance population represents 10% of the US population and, in 2007, represented 470,646 live births (11%).
Pregnant and postpartum case patients were restricted to women 15-44 years of age, because very few (1%) pregnant cases occurred outside this age range and national pregnancy denominator data were not available outside this age range [27] . As a comparison group, nonpregnant case patients were similarly restricted to women aged 15-44 years, because age and sex are associated with invasive bacterial infection incidence and age is associated with severity [14, 15, [28] [29] [30] [31] . Pregnant or postpartum (within 30 days of delivery) status was recorded at time of culture.
Disease Incidence
To calculate disease incidence, we estimated the national number of cases by applying race-and age-specific rates of disease from the aggregate surveillance area to the age and race distribution of the annual US population during 2007-2009. Case patients with unknown race were distributed by area on the basis of reported race distribution for known cases in the 15-44 years of age category.
For denominators, we estimated the number of pregnant, postpartum, and nonpregnant women nationally with use of methods published elsewhere [11, 32] . We multiplied annual racespecific (white, black, and other race) fertility rates for women aged 15-44 years by nine-twelfths of the race-specific population of women [33, 34] . We then added to this the annual abortion rate multiplied by one-sixth of the race-specific population of women (2007 fertility and 2005 abortion rates were used for all years) [33] . For postpartum women, we multiplied live birth estimates for 2008, adjusted to exclude multiple births (3.4% of births) [33] by 30 d/365.33 d or approximately one-twelth to account for the limited exposure time of postpartum women. Nonpregnant population estimates were obtained by subtracting racespecific estimates of the pregnant and postpartum population from the corresponding total US population of women. Confidence intervals (CIs) around the standardized incidence estimates were calculated using a method derived from the relationship between Poisson and c distributions [35] .
Disease Severity
We used hospital length of stay (LOS) as an indicator of disease severity. Because the mean US hospital LOS for females aged 15-44 years for all causes was 3.3 days in 2006 [36] , LOS was categorized as ,4 or $4 days. We did not use hospitalization to indicate disease severity, because 88% of case patients, regardless of pathogen, were hospitalized. Outcome (died vs survived) was not evaluated as an indicator of disease severity, because only 2 pregnant or postpartum women died after infection due to any of the 3 pathogens. Outcome was assessed at hospital discharge and pertains only to that hospitalization.
Variables assessed for association with LOS included pregnancy or postpartum status, age, race, syndrome caused by infecting pathogen, and $1 underlying illness. For each pathogen, age was categorized as less than or equal to median age or greater than median age. Race was categorized as black versus nonblack, because past surveillance data showed a higher disease incidence among black persons, compared with nonblack persons for the 3 pathogens [37] [38] [39] . Pathogen-associated syndromes were categorized according to the overall case-fatality rates in ABCs for each syndrome among women aged 15-44 years during 2007-2009. High case-fatality rate syndromes included bacteremia without focus, meningitis, empyema, epiglottitis, necrotizing fasciitis, peritonitis, pneumonia, and streptococcal toxic shock syndrome; low case-fatality rate syndromes included abscess (not skin), cellulitis, chorioamnionitis, endocarditis, endometritis, hemolytic uremic syndrome, osteomyelitis, otitis media, pericarditis, puerperal sepsis, septic abortion, and septic arthritis.
Underlying condition was defined as documentation of any of the following in the case patients medical record: smoker, multiple myeloma, sickle cell anemia, splenectomy and/or asplenia, immunoglobulin deficiency, immunosuppressive therapy (steroids, chemotherapy, or radiation), leukemia, Hodgkin disease, asthma, emphysema and/or chronic obstructive pulmonary disease, systemic lupus erythematosus, diabetes mellitus, nephrotic syndrome, renal failure and/or dialysis, HIV infection, AIDS or CD4 cell count ,200 cells/mm 3 , cirrhosis and/or liver failure, alcohol abuse, atherosclerotic cardiovascular disease, heart failure, burns, cerebrospinal fluid leak, injection drug use, malignancy, or organ transplantation. Burns and varicella were included as underlying conditions on GAS case report forms. HIV infection and AIDS or CD4 cell count ,200 cells/mm 3 are not reported in New York. Because 75% of case patients not in New York who had these conditions had a second underlying medical condition, we included New York in our analysis for disease severity, recognizing that some small proportion of these patients may have had HIV infection or AIDS or CD4 cell count ,200 cells/mm 3 as the sole underlying condition. HIV infection and AIDS or CD4 cell count ,200 cells/mm 3 were considered to be mutually exclusive conditions.
Statistical Analysis
Analyses were performed using SAS, version 9.2 (SAS Institute). Categorical variables were analyzed using Wald v 2 or Fisher's exact tests, and a 2-tailed P value ,.05 was considered to be statistically significant. Risk factors associated with disease severity were analyzed using logistic regression. All factors evaluated by univariate analysis were included in multivariable models; we checked multivariable models for all 2-way interactions and collinearity.
RESULTS
Descriptive Characteristics of Case Patients
During 2007-2009, 999 pneumococcus cases, 439 GAS cases, and 410 GBS cases were identified; 43 (4%) of the pneumococcus cases were in pregnant women, and 16 (2%) were in postpartum women (Table 1) ; 25 (6%) of the GAS cases were in pregnant women, and 65 (15%) were in postpartum women (Table 2) ; and 42 (10%) of the GBS cases were in pregnant women, and 57 (14%) were in postpartum women (Table 3) . Case-fatality rates among pregnant, postpartum, and nonpregnant women combined ranged from 3% (GBS) to 9% (GAS). For all 3 pathogens, nonpregnant case patients were more likely to be older than pregnant and postpartum women and were more likely to have $1 underlying medical condition. Very few women in any group had a pneumococcal infection caused by a serotype in the 7-valent conjugate vaccine, in use since 2000. For pregnant and postpartum women with pneumococcal disease, infection with the 6 serotypes unique to the 13-valent pneumococcal conjugate vaccine licensed in February 2010 was higher, compared with nonpregnant women (54% vs 44%; P 511). Among women with GAS infection, emm subtypes 1 and 28 were the most frequently identified overall, with subtype 28 more common among pregnant and postpartum women, compared with nonpregnant women (P 5004), and subtype 1 most common among nonpregnant women (Table 2) .
Data on fetal outcome were available for 72% of pregnancy and postpartum cases. Fetal outcome varied among the pathogens. Among women with pneumococcus (n 5 59), there were 5 abortions and/or still births (8%); for GBS (n 5 99), there were 24 abortions and/or still births (24%), and 2 live births and/or neonatal deaths (2%). Among all women with GAS (n 5 90), there were 5 abortions and/or still births (6%) and 2 live births and/or neonatal deaths (2%).
Disease Incidence
We estimated an annual mean of 3,400,000 pregnant, 343,000 postpartum, and 58,000,000 nonpregnant and/or postpartum women during 2007-2009, totalling 62 million women per year. The overall incidence of pneumococcus (0.05 cases/1000 women) was higher than for GAS disease (0.02 cases/1000 women) or GBS disease (0.02 cases/1000 women) ( Table 4) . Pneumococcus and GAS incidence did not differ significantly between pregnant and nonpregnant women (Table 4 ). In contrast, pregnant women had a higher GBS disease incidence than nonpregnant women (0.04 vs. 0.02). Postpartum women had an elevated incidence of all 3 pathogens, compared with nonpregnant women (pneumococcus: 0.15 vs 0.05; GAS: 0.56 vs 0.02; GBS: 0.49 vs 0.02) ( Table 4) . (Table 5) . Older age was associated with longer hospital LOS among women with invasive pneumococcal disease in multivariable analysis (adjusted odds ratio [aOR], 1.64; 95% CI, 1.25-2.15) but not for GAS or GBS. Black race and syndromes with a high case-fatality rate were not associated with longer hospital LOS for any of the pathogens, but the presence of $1 underlying illness was associated with longer LOS for GAS and GBS (GAS: aOR, 1 
DISCUSSION
S. pneumoniae, GAS, and GBS result in .75,000 invasive cases annually in the US population [40] [41] [42] . To our knowledge, this is the first multistate, population-based evaluation of pregnancy-and postpartum-associated community-acquired invasive streptococcal infections. Pregnancy was associated with a 2-fold increased incidence of GBS disease, compared with nonpregnant women of similar age, and the postpartum women had a 20-fold increased incidence of GAS and GBS, compared with nonpregnant women (Table 2) . Neither pregnancy nor postpartum status was associated with longer hospital LOS for any of the pathogens.
Reasons for the increased incidence of invasive GAS and GBS disease among postpartum women and the decreased postpartum effect on incidence for invasive pneumococcal disease are not clear. The mean incidence among postpartum women for GAS and GBS is higher than that observed among adults aged $65 years, a group well established as being at increased risk of GAS and GBS infections [14, 43] . Invasive GBS infection in nonpregnant adults is strongly associated with having an underlying medical condition (71%, with diabetes present in 28%) [43] . Of note, only 28% of postpartum women had at least one underlying condition, and none had gestational diabetes. For GAS, only 23% of postpartum women had an underlying illness, compared with 50% of (5) 1 (6) 1 (2) 14 (6) 28 43 (14) 4 (22) 12 (24) 27 (11) 89 23 (7) 1 (6) 7 (14) 15 (6) a Race: Documented black versus all others.
b Other syndromes include: puerperal sepsis, septic abortion, cellulitis, peritonitis, empyema, epiglottis, endocarditis, meningitis, necrotizing fasciitis, abscess (not skin), hemolytic uremic syndrome, osteomyelitis, septic arthritis, and other (lymphadenitis, lymphadenopathy, necrotizing lymphadenopathy).
c High case-fatality rate syndrome was defined as having bacteremia without focus, meningitis, empyema, epiglottitis, necrotizing fasciitis, peritonitis, pneumonia and streptococcal toxic shock syndrome.
d Underlying medical conditions include: smoker, multiple myeloma, sickle cell anemia, splenectomy/asplenia, immunoglobulin deficiency, immunosuppressive therapy (steroids, chemotherapy, radiation), leukaemia, Hodgkin's disease, asthma, emphysema/COPD, systemic lupus erythematosus, diabetes mellitus, nephrotic syndrome, renal failure/dialysis, HIV infection, AIDS or CD4 count ,200, cirrhosis/liver failure, alcohol abuse, atherosclerotic cardiovascular disease, heart failure, burns, CSF leak, IVDU, other malignancy, organ transplant, other prior illness; burns and varicella were also included as underlying conditions on GAS case report forms. e 2 persons with unknown outcome excluded from analysis.
f Serotypes available for 312 (71%) GAS isolates.
nonpregnant women, which suggests that the postpartum status increases susceptibility. In contrast to influenza, we found no evidence that pregnancy or postpartum-associated infections were associated with a longer hospital LOS or increased risk of death [44] . Invasive bacterial infections may actually be milder in pregnant women who may be hospitalized from an abundance of caution. Although maternal outcomes may not have been affected, loss of the fetus, newborn death, or birth of a newborn with clinical illness also represent adverse outcomes that may be linked to maternal infection. The proportion of pregnant and postpartum women with invasive streptococcal infection who experience a still birth or neonatal death (6%-24%) was notably elevated, compared with the national estimate of ,1% [45] , suggesting that maternal infection has severe consequences for the newborn.
Although all 3 pathogens belong to the streptococcus genus, our observation of no effect of pregnancy on incidence of GAS and invasive pneumococcal disease and the more pronounced effect of the postpartum status on incidence of GAS and GBS underscores the importance of pathogen-specific evaluations of the association between pregnancy, postpartum status, and infection risk and cautions against across-pathogens generalizations. A better understanding of why pregnancy and postpartum status impact infection with these streptococcal pathogens b Other syndromes included: peritonitis, pneumonia, meningitis, necrotizing fasciitis, streptococcal toxic shock syndrome, endocarditis, pericarditis, septic arthritis, puerperal sepsis, abscess (not skin), osteomyelitis, and other (cystitis, hydronephrosis, lumbar spinal subdural empyema (SSE)).
d Underlying medical conditions include: smoker, multiple myeloma, sickle cell anemia, splenectomy/asplenia, immunoglobulin deficiency, immunosuppressive therapy (steroids, chemotherapy, radiation), leukemia, Hodgkin's disease, asthma, emphysema/COPD, systemic lupus erythematosus, diabetes mellitus, nephrotic syndrome, renal failure/dialysis, HIV infection, AIDS or CD4 count ,200, cirrhosis/liver failure, alcohol abuse, atherosclerotic cardiovascular disease, heart failure, burns, CSF leak, IVDU, other malignancy, organ transplant. e 2 persons with unknown outcome excluded from analysis.
f Serotypes available for 218 (53%) GBS isolates, 8 nontype.
and why the postpartum status causes a marked predisposition for GAS and GBS infections may shed light on why they are important risk factors for some other pathogens. Currently, S. pneumoniae is the only pathogen with a licensed available adult vaccine, the 23-valent pneumococcal polysaccharide vaccine (PPSV23). Current guidance does not list pregnancy as a vaccine indication, and our findings support this. Although influenza infection is a well-established risk factor for secondary serious pneumococcal infection and although pregnant women are at elevated risk of influenza infection, our findings also suggest that targeted pneumococcal vaccination of pregnant women during an influenza pandemic may not be warranted.
Vaccines for GAS [16] and GBS [17] are under development, but no licensed products are currently available. GAS vaccine development for the US market is targeted toward preventing pharyngitis and sequelae among school-aged children. If a GAS vaccine is licensed to prevent invasive disease, the likely initial target age group would be infants and young children. Our observation that postpartum women had an incidence equal to or higher than that among older adults, the age group with the highest incidence, suggests that pregnancy may warrant consideration as an indication, assuming the vaccine is safe and effective for this population. For GBS, the most likely target will be prevention of neonatal infections. Vaccine implementation strategies under consideration include vaccination during pregnancy and vaccination of adolescent girls. Our observation of elevated disease incidence among pregnant and postpartum women suggests that either strategy would offer mothers direct protection against infection. Such direct protection should also be considered as the theoretical safety concerns about vaccination during pregnancy are weighed against the potential GBS disease burden prevented.
Our evaluation of pregnancy-and postpartum-associated infections had several limitations. Although ABCs detects invasive cases of disease, most cases of clinical endometritis are not evaluated using sterile site cultures [46, 47] , because endometritis may be successfully treated with empirical antibiotics [46, 48] . Therefore, the total burden of invasive postpartum streptococcal disease is probably underestimated. We did not have detailed clinical data, particularly with respect to severity; thus, we could only evaluate hospital LOS and patient outcome as severity proxies. We also did not have clinical data pertaining to coinfection with influenza, a pathogen that can predispose to secondary bacterial infections. Our data collection period included the 2009 H1N1 pandemic; although annual rates had wider CIs than did the aggregate 3-year rate, there was no evidence of markedly elevated rate of streptococcal infection in 2009. We had limited information on fetal and neonatal outcome, particularly for pregnant women who did not deliver or have a pregnancy loss during the course of their invasive disease episode. Because pregnancies do not last a full year, the person-time associated with disease incidence in pregnant versus nonpregnant women is difficult to estimate. Our estimation of denominators also had several limitations. We had no underlying medical condition information and, thus, could not adjust for the effect of these in our incidence comparisons. Although the estimated denominators take into account race-specific fertility and induced abortion rates, they do not incorporate several assumptions associated with pregnancy time at-risk, such as fetal mortality, seasonality of pregnancies, and distribution of pregnancy durations. Finally, our estimated postpartum denominator was based on live births because specific data on fetal mortality, particularly late-term fetal losses, which may result in similar physiological risk of infection to live birth, were not available for our study period. However, on the basis of data from 2005, fetal losses overall represented 0.5% of all deliveries, with late-term fetal losses accounting for approximately one-half of all fetal losses; therefore, our estimates of postpartum incidence will be negligibly affected by this limitation [49] .
Although there are 6 million pregnancies/y in the United States and most women are pregnant at some point in their lifetimes, the epidemiology of infections during the pregnant and postpartum periods and the impact of pregnancy and postpartum status on infectious disease risk and severity is poorly characterized for most pathogens. For safety reasons and concerns about generalizability and human subjects research protections, pregnant and postpartum women are also often excluded from trials evaluating vaccines and therapies. The variation that we observed in the impact of pregnancy and the postpartum status on disease burden of S. pneumoniae, GAS, and GBS and the additional contrasts between these bacterial pathogens and the pregnancy and postpartum associations documented for influenza underscore the importance of careful pathogen-specific evaluations and the importance, for some pathogens, of considering pregnant and postpartum women as an at-risk group requiring targeted prevention and control efforts. 
